Melanotan-1 10mg Skin Tanning Peptides
Product Name: Melanotan-1 10mg
Synonyms: Melanotan-1 ; MT1; MT-1
Specifications: 10 vials per kit/box
CAS No. 75921-69-6
Purity: 99%
Appearance: White lyophilized powder
Package: Discreet and secure
Shipping: Safety and fast, guarantee delivery
Storage: Lyophilized peptides to be stored below -18°C
Research use only. Not for human or animal consumption!
What is Melanotan 1 peptide?
MELANOTAN 1 (MT-1) is a synthetic equivalent of alpha-melanocyte-stimulating hormone (alpha-MSH). In Europe, the peptide is clinically administered to patients suffering from erythropoietic protoporphyria to prevent phototoxicity or sun-related skin damage. It was initially formulated to act as a sunless tanning agent. Interestingly, it was also observed to influence diverse physiological processes like feeding patterns, central nervous system operations, blood pressure, etc. The molecule’s clinical trials are currently in phase II stage for keratosis (a particular kind of skin damage induced by the sun). The more severe squamous cell carcinoma is in phase III stage to treat polymorphous light eruption.
How Does MT-1 Work?
MELANOTAN 1 is structurally and functionally similar to the physiological alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is primarily known to affect melanocytes, skin cells, and hair cells responsible for pigmentation. The hormone interacts strongly with melanocortin receptor 1, thus mediating its role. Alpha-MSH is a non-selective agonist of melanocortin receptors 1, 3, 4, and 5 and completely stimulates them.
MT-1 varies from alpha-MSH by single amino acid and was initially developed as a sunless tanning agent. It was soon discovered that MT-1 also induces sexual arousal, boosts appetite, and modifies baseline metabolism apart from affecting skin pigmentation. Subsequent research on the peptide and other melanocortin-binding proteins helped scientists to explore the melanocortin signaling system better.
Uses of Melanotan 1
The main uses of the Melanotan I peptide are:
Used in the management of erythropoietic protoporphyria
Used to induce skin tanning, as desired
Used indoors without sunlight exposure
Used outdoors, safely in combination with sunlight
Research and Clinical Studies on Melanotan
Clinical Trials on Patients Suffering from Erythropoietic Porphyria
There were three clinical trials (6) conducted to examine the effects of Melanotan on the erythropoietic porphyria patients. Trials were conducted in 244 patients, both males and females, and mostly aged between 18 to 64 years.
Trial I
All patients were divided into two groups, one that was treated with the peptide and the other that was treated with placebo. Patients received the implants (of either the peptide or placebo) every two months and were monitored for 180 days. The patients reported the number of hours they were exposed to direct sunlight and if they experienced any pain on sunlight exposure.
Trial II
Similar to Trial I, patients were divided into groups receiving the implants (of either the peptide or placebo) every two months and were monitored for 270 days.
Trial III
In this trial, patients were subject to a randomized study where they received a total of 3 implants of either the Melanotan I or the placebo, via subcutaneous route and were monitored for 180 days. The main aim of this trial was to assess any potential adverse effects of the peptide.
The outcome of this study was that the patients who received the peptide were able to spend more time in sunlight with no pain (approximately 64 hours) as compared to patients who were treated with placebo (approximately 40 hours).
Reviews
There are no reviews yet.